Researchers have recently uncovered how specific signaling pathways regulate CAF plasticity in CRC, offering new insights into the tumor microenvironment. Cancer-associated fibroblasts (CAFs) are not a uniform population. Instead, they exist in distinct states like inflammatory CAFs (iCAFs) and myofibroblast-like CAFs (myCAFs). Notably, iCAFs secrete cytokines that recruit immune cells, while myCAFs focus on remodeling the extracellular matrix. This phenotypic switching significantly impacts how colorectal tumors grow and respond to medical interventions.

Understanding CAF Plasticity in CRC via PI3K and MAPK

The study utilized single-cell RNA sequencing and 3D human cultures to map the signaling architecture of CAFs. Consequently, the team discovered that the PI3K/mTOR and MAPK/ERK pathways act as divergent drivers of fibroblast behavior. Specifically, the PI3K/mTOR pathway is associated with the myCAF state. Meanwhile, the MAPK/ERK pathway supports the iCAF phenotype. When researchers inhibited these pathways, they observed a dramatic shift in CAF identity.

The Impact of Targeted Inhibitors on the Stroma

Blocking PI3K/mTOR signaling did not just stop growth; it actively drove the formation of iCAFs. This process occurred through a compensatory release of FGF-2, which then activated the FGFR1-JAK2-STAT3 signaling axis. These newly formed iCAFs increased cytokine secretion, promoting tumor growth and attracting neutrophils. Conversely, MEK inhibition induced a transition toward the myCAF phenotype. This shift, mediated by interferon-dependent ROCK and JAK1 signaling, led to increased matrix deposition and enhanced tumor colony formation.

Furthermore, these findings suggest that standard-of-care targeted therapies may have unintended consequences on the tumor stroma. Therefore, clinicians must consider how inhibiting one pathway might inadvertently reprogram the microenvironment to favor different tumor-promoting mechanisms. Moreover, reprogramming CAFs could eventually become a viable strategy to enhance the efficacy of existing colorectal cancer treatments.

Frequently Asked Questions

What are the primary subtypes of CAFs in colorectal cancer?

The two main subtypes are inflammatory CAFs (iCAFs), which produce cytokines and chemokines, and myofibroblast-like CAFs (myCAFs), which focus on extracellular matrix deposition and actomyosin contractility.

How do PI3K and MAPK inhibitors affect CAF phenotypes?

PI3K/mTOR inhibitors can push fibroblasts toward an inflammatory iCAF state via FGF-2 release. In contrast, MEK (MAPK) inhibitors tend to drive them toward a myofibroblast-like myCAF state through interferon-dependent signaling.

Why is CAF plasticity important for cancer treatment?

CAF plasticity allows the tumor microenvironment to adapt to therapeutic cues. Understanding these shifts helps researchers develop strategies to prevent CAFs from adopting states that promote tumor survival or drug resistance.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Xia Z et al. PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer. Cancer Res. 2026 Mar 12. doi: 10.1158/0008-5472.CAN-25-0766. PMID: 41817574.

Pitts TM et al. Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer. PLoS ONE. 2014;9(11):e113037.

Brandão M et al. The Role of PI3K Inhibitors in Cancer Therapy: Current Evidence and Future Directions. Frontiers in Oncology. 2021;11:645362.